Key result
Current evidence for treating lipid abnormalities in patients with chronic and end-stage kidney disease is lacking, necessitating future studies on pathophysiological mechanisms and treatment.
This review highlights the lack of evidence for treating dyslipidemia in patients with chronic and end-stage kidney disease and calls for further research.
Insufficient evidence precludes lipid management guidance in CKD/ESKD; leaves open mechanistic and therapeutic research priorities.
In this review, we discuss the physiology, diagnosis and treatment of dyslipidemia in patients with chronic and end-stage renal disease. The recent important clinical trials in patients with chronic kidney disease and dyslipidemia are reviewed. Because of the lack of evidence in treating lipid abnormalities in this specific patient population, we propose that future studies should focus on the pathophysiological mechanisms and treatment of dyslipidemia in this special patient population.
No takes yet. Share an insight, caveat, or question.
Omran et al. (2013) conducted a review in Chronic and end-stage kidney disease with dyslipidemia. Current evidence for treating lipid abnormalities in patients with chronic and end-stage kidney disease is lacking, necessitating future studies on pathophysiological mechanisms and treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: